Guest guest Posted March 27, 2010 Report Posted March 27, 2010 Wayne,This is indeed a very good topic, but it looks like researchers do not have a clear picture themselves. This is due to the fact that, when we look at aspirin intolerance (AI), we are in fact speaking of a conglomerate of overlapping subsets. AERD is a subset of AI, and it may overlap with, aspirin-induced urticaria, and, more rarely, with other aspirin-induced conditions. Then, neither is AERD a homogeneous set itself ; it has several components that can be classified according to area of exacerbation (upper airways alone or both upper and lower airways), the severity of polyposis, the genetic origin(s) of the AE, etc. This also reflects the observation that we are all different cases. When we get to the mechanism level, the most prevalent one is the Arachidonic Acid pathway, but a lot of other reactions happen around at the same time, with IgE, lipoxins, CysLT receptors, etc. Researchers have still a long way to go to elucidate how all these reactions and mediators interact together, and it will be a tough job because the order of prevalence of these reactions may vary from one subset to the other. Regarding the IgE-mediated anaphylactic shock, - Jenneck et al write that : "However, some patients develop an anaphylactic reaction with acute urticaria and angioedema or even anaphylactic shock after the second exposition to NSAIDs or aspirin, although it has been well tolerated during previous applications. In these cases, the reactions are based on the development of drug specific IgE antibodies against aspirin21 or NSAIDs, which explains the relatively low rate of cross reactions to other NSAIDs observable in these patients.22" 21 and 22 being : 21. Blanca M, E, JJ, et al. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy. 1989;62: 295–298. 22. Simon RA. Prevention and treatment of reactions to NSAIDs. Clin Rev Allergy Immunol. 2003;24:189 –198. Ann Allergy. 1989 Apr;62(4):295-8. Angioedema and IgE antibodies to aspirin: a case report. Blanca M, E, JJ, Miranda A, Terrados S, Vega JM, Suau R. Internal Medicine Department, Haya Hospital, Malaga, Spain. We present a case of a patient who developed two episodes of angioedema after taking acetylsalicylic acid orally. Specific IgE antibodies to acetylsalicylic human serum albumin (ASA-HSA) were found. A control group of 37 patients with aspirin intolerance was studied and evidence of specific IgE antibodies was not found. The follow-up of this case shows that in a short period of time the level of specific IgE antibody decreases to undetectable levels similar to the negative control population. ------------- - so, apparently, IgE antibodies specific to ASA-HSA apparently do exist, but this is rare, or not easily detectable because even in this case, the specific IgE return to zero after the event. -------------- Clin Rev Allergy Immunol. 2003 Apr;24(2):189-98. Prevention and treatment of reactions to NSAIDs. Simon RA. Divison of Allergy, Asthma, and Immunology, The Scripps Clinic and Research Institute, La Jolla, CA 92037, USA. rsimon@... Avoidance of ASA and other NSAIDs prevents the reactions and careful attention to clinical history along with patient education are important. However, blanket advice to avoid all NSAIDs is no longer reasonable. Except for AERD and chronic urticaria, cross-reactivity with other NSAIDs does not occur. A physician can definitively prove this by giving the patient another NSAID in their office and observing no reaction. Furthermore, for patients with AERD and chronic urticaria, they can be given the new selective COX-2 inhibitors (rofecoxib and celecoxib) without any cross-reactivity. All AERD patients can be desensitized to ASA and treated with ASA indefinitely. However, ASA desensitization in chronic urticaria is not possible. Underlying mild and moderate AERD responds well to topical and systemic corticosteroids and leukotriene modifiers. However, the severe forms of the disease should be desensitized to ASA and treated with this drug on a long term basis. In the future, new drugs that prevent eosinophil activation and chemotaxis or enhance eosinophil apoptosis are likely to be useful. Specific blockers of the second cystLT receptor would also be useful. Ultimately as the genetics of these heterogeneous disorders are unraveled, gene substitution therapy may be the ultimate answer. ------------ and here I have not read the entire article, but I am not convinced at all by some of the across-the-board assertions in the abstract, notably that "All AERD patients can be desensitized and treated with ASA indefinitely". The abstract does not mention IgE, so I can't say what evidence RA Simon has to present. From the above, it would seem that IgE-mediated ASA hypersensitivity is rare, and that it is difficult to say whether the apparition of specific IgE antibodies against ASA results from a condition distinct from the one resulting from AA metabolism, or whether it is linked to it. To add to this possibility, some hypersensitivity specialists have now put forth the hypothesis that NSAID hypersensitivity does come from AA metabolism, and is explained by dose-dependance : "The finding that clinical hypersensitivity to NSAIDs is often accompanied by dose-dependent in vitro basophil hypersensitivity is not revolutionary. It corresponds rather well with the hypothesis that NSAID hypersensitivity is not an immunological but a pharmacological phenomenon related to the inhibitory effect of these drugs on prostaglandin synthesis [4]. The fact that some controls that are clinically tolerant to NSAIDs show positive BAT results and that some clinically hypersensitive patients show negative BAT results does not invalidate the hypothesis. It is well documented that the minimum NSAID dose needed to elicit clinical symptoms can vary by a factor of as much as 100 (eg, 5-500 mg) in hypersensitive patients." in : J Investig Allergol Clin Immunol. 2009;19(5):355-69. Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter study. I. Clinical findings and in vitro diagnosis. De Weck AL, Sanz ML, Gamboa PM, Aberer W, Blanca M, Correia S, Erdman S, Jermann JM, Kanny G, Kowalski M, Mayorga L, Medrala W, Merk A, Sturm GJ, Sainte-Laudy J, Schneider MS, Sczczeklik A, Weber JM, Wedi A. Department of Allergology and Clinical Immunology, Clinica Universidad de Navarra, Collaborative center of Pamplona, Spain. --------- Personally, I do believe like you that many groups are likely to overlap, and I also believe that genetic polymorphisms and dose-dependance might explain the spectrum of reactions to ASA. The clinical implications of this for us, who belong to the AERD subset of aspirin intolerance, is that this results in impaired host defense of the airways and facilitates both the development of allergies and colonization by pathogens such s biofilms. Let us also remember that we may have ASA-independant conditions in addition ! ----------- Allerg Immunol (Paris). 2001 Mar;33(3):120-6. [Acetylsalicylic acid: hypersensitivity, intolerance, or allergy?] [Article in French] Sainte-Laudy J. Unité d'immuno-allergologie, Laboratoire Pasteur-Cerba, 95066 Cergy-Pontoise. After a century of therapeutic use of acetyl salicylic acid (ASA), the different mechanisms involved leading to the therapeutic activity and to the various clinical reactions (even life threatening) observed in patients sensitive to ASA or in general to the non steroidal anti-inflammatory drugs (NSAID's) are still to be discovered or confirmed. During the last century a lot of scientific results have been published in favour of a wide panel of mechanism including an humoral (IgE and/or IgG) or a cellular (lymphocytes) immune reaction, inhibition of the cyclooxygenases, a cellular activation (mast cells, basophils, eosinophils and platelets), a competition at the serum albumin level and an activation of the complement cascade. In general the same actors than in the anaphylactic reaction are found (mediators, cellular activation and amplification systems). It is clear today that these reactions for which an accurate diagnosis is mandatory cannot be explained by a single mechanism, which is the case of a lot of other allergens. >> Pathogenesis,diagnosis, and treatment of aspirin intolerance,Jennek et al,Ann Allergy Asthma immunol,Vo 99,July2007,pgs13-21. > This summary discusses two groups of AI. One hypothesis proposes that AI results directly from an unspecific,non IgE-dependant degranulation of mast cells and eosinophils in an pseudoallergic reaction in which symtoms appear after the first intake of the drug (ASA or another NSAID).These reactions were associated with increased Cys-LTs and eosinophilic cationic protein( ie reactions related to COX-1 inhibition ) reflecting activation of eosinophils and an increase in prostaglandin D2 which mirrors mast cell activation.Studies showing increased histamine and trytase levels after taking asa in AI individuals without detection of asa specific IgE supports the pseudoallergic theory as a cause for AI in most cases.Desensitization for these individuals would seem a safer procedure. > However in another group of AI individuals exposure to an NSAID can result in anaphylaxis(IgE mediated reaction).Anaphylactoid reactions with acute urticaria and angioedema or even anaphylactic shock. Repeated exposure(desensitization) to an NSAID leads to saturation of anti-NSAID IgE antibody binding sites on mast cells and basophils.Desenitization in this group of AI individuals only under medical supervision where equipped to handle anaphylaxis.Cross reactivity is not as generallized as in the first group( ie antibody specfic) > Correct me if I am wrong but the urticaria can exist in both groups.Also it would make sense that these two groups might overlap to some extent.An interesting discussion would involve when an individual with AI develops the IgE specific reactions because this must be mostly where the desensitization risks lie. Wayne> Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.